极速赛车

December 16, 2020

In re Xyrem (Sodium Oxybate) Antitrust Litigation

View recent docket activity


Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.


Coverage

  1. May 08, 2025

    Hikma Cuts $50M Deal To End Antitrust Claims In Xyrem MDL

    A certified class of Xyrem buyers in 36 states have asked a California federal judge to preliminarily approve Hikma Pharmaceuticals PLC's $50 million deal to resolve antitrust claims accusing Hikma of colluding with rival Jazz Pharmaceuticals to block generic rivals from competing with Jazz's narcolepsy drug.

6 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what鈥檚 happening with clients, competitors, practice areas, and industries. 极速赛车 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS